Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?

The most important factor associated with liver-related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison et al. 1 Harrison S.A. Bedossa P. Guy C.D. Schattenberg J.M. Loomba R. Taub R. Labriola D. Moussa S.E. Neff G.W. Rinella M.E. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N. Engl. J. Med. 2024; 390: 497-509https://doi.org/10.1056/NEJMoa2309000 Crossref PubMed Scopus (34) Google Scholar demonstrated the efficacy of resmetirom, a selective THR-β agonist, for the treatment of MASH and liver fibrosis at 52 weeks. The most important factor associated with liver-related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison et al. 1 Harrison S.A. Bedossa P. Guy C.D. Schattenberg J.M. Loomba R. Taub R. Labriola D. Moussa S.E. Neff G.W. Rinella M.E. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N. Engl. J. Med. 2024; 390: 497-509https://doi.org/10.1056/NEJMoa2309000 Crossref PubMed Scopus (34) Google Scholar demonstrated the efficacy of resmetirom, a selective THR-β agonist, for the treatment of MASH and liver fibrosis at 52 weeks.